Aeter­na Zen­taris dou­bles down on maci­more­lin PhI­II, and los­es

Two years af­ter the FDA hand­ed Aeter­na Zen­taris a sting­ing re­jec­tion for its pro­pos­al to mar­ket maci­more­lin for the eval­u­a­tion of growth hor­mone de­fi­cien­cy in adults, the biotech says the drug flunked an­oth­er late-stage study.

Just as Aeter­na Zen­taris wit­nessed in late 2014, its stock $AEZS cratered, drop­ping by about 50% in af­ter-mar­ket trad­ing.

The FDA sent Aeter­na Zen­taris back to the clin­i­cal draw­ing board af­ter point­ing out that maci­more­lin had failed to hit the pri­ma­ry end­point. Aeter­na Zen­taris moved from Cana­da down to Charleston, SC more than two years ago, promis­ing to cre­ate 60 jobs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER